MiR-200a impairs glioma cell growth, migration, and invasion by targeting SIM2-s

Yuhang Su1, Qiaowei He, Lin Deng

  • 1Departments of aEmergency Surgery bNeurosurgery, Qilu Hospital of Shandong University cBrain Science Research Institute, Shandong University, Jinan dDepartment of Neurology, The Affiliated Yantai Yuhuangding Hospital of Qingdao Medical College, Yantai, China.

Neuroreport
|October 29, 2013
PubMed

Insights

Single-minded homolog 2-short form (SIM2-s) is elevated in gliomas, promoting tumor growth. Restoring miR-200a levels could offer a new therapeutic strategy for glioma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Single-minded homolog 2-short form (SIM2-s) is implicated in tumor development and progression.
  • Elevated SIM2-s levels are observed in various human cancer cells, suggesting its oncogenic role.

Purpose of the Study:

  • To investigate the regulatory factors of SIM2-s expression in gliomas.
  • To explore the potential of miR-200a as a therapeutic target for glioma.

Main Methods:

  • Quantitative analysis of SIM2-s expression in glioma tissues.
  • In vitro experiments assessing the impact of SIM2-s inhibition on glioma cell behavior.
  • Luciferase reporter assays to confirm SIM2-s as a target of miR-200a.
  • In vivo studies using a mouse model of human glioma.

Main Results:

  • SIM2-s expression is significantly elevated in gliomas.
  • Inhibition of SIM2-s suppressed glioma cell proliferation, migration, and invasion.
  • miR-200a was found to be downregulated in human glioma and directly targets SIM2-s.
  • Downregulation of miR-200a led to increased SIM2-s expression and enhanced T98G cell motility.
  • Blocking miR-200a in a mouse glioma model promoted tumor growth.

Conclusions:

  • SIM2-s plays a crucial role in glioma progression.
  • miR-200a acts as a tumor suppressor in gliomas by downregulating SIM2-s.
  • Restoring miR-200a levels presents a potential therapeutic strategy for glioma.